The change from NAFLD to MAFLD expands fatty liver information flow

Fouad, Yasser; Salam, Sherief Abdel; AbdAllah, Mohamed; Attia, Dina

doi:10.1111/hepr.13752

Cited by 2 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 39 , 40 Furthermore, after introduction of the term MAFLD, several sessions and lectures at numerous international meetings were dedicated to the topic. 41 This is a very important aspect as proper management of this disease in the future throughout the world will only be possible when primary care physicians, diabetologists and gastroenterologists/hepatologists are perfectly aware of the relevance and importance of this disease. Another report into this direction was recently presented by Farahat et al 42 proposing that such a definition might enhance awareness globally in primary care.…”

Section: Evidence That the New Definition ‘Mafld’ Might Advance The F...mentioning

confidence: 99%

MAFLD: what 2 years of the redefinition of fatty liver disease has taught us

Grabherr

Grander

Effenberger

et al. 2022

Therapeutic Advances in Endocrinology

View full text Add to dashboard Cite

Metabolic dysfunction–associated fatty liver disease (MAFLD) has appeared as the leading liver disease worldwide. Whereas the terminology nonalcoholic fatty liver disease (NAFLD) mainly reflected a negative selection and exclusion of alcohol-related liver disease (ALD), the new definition made its focus on the association of MAFLD with overweight/obesity, type 2 diabetes and metabolic risk factors especially also in normal weight/lean subjects. Several studies from the past 2 years have now used the new definition and have provided substantial information that this new definition might be accurate. Studies from the past 2 years have provided evidence that the new definition might be especially advantageous in the characterization and identification of patients with significant fibrosis. This has also been demonstrated in the well-known Rotterdam study in which the MAFLD-only group showed a higher rate of fibrosis and liver stiffness. MAFLD might also be able to predict all-cause mortality as demonstrated in the Third National Health and Nutrition Examination Survey. Furthermore, MAFLD might improve characterization of the cardiovascular risk of this patient population. As the term MAFLD has not yet been accepted universally, it remains important to coordinate efforts globally to adapt to this new definition and especially involve all specialities dealing with metabolic disorders such as diabetologists to further improve its definition and to prepare the medical community for its future use. The aim of this review is to summarize and critically address evidence emerging over the past 2 years that usage of the term MAFLD could be helpful in daily clinical practice.

show abstract

Section: Evidence That the New Definition ‘Mafld’ Might Advance The F...mentioning

confidence: 99%